BeiGene Ltd's (6160) shares surged 7.74% in the intraday trading session on Friday, riding on the crest of robust revenue growth and a promising outlook for the oncology treatments developer.
The Hong Kong-listed stock hit a three-year high of HK$174.8, reflecting investors' enthusiasm for the company's stellar performance. BeiGene reported a remarkable 78% year-over-year increase in total global revenues to $1.1 billion for the fourth quarter of 2024 and a 55% year-over-year increase to $3.8 billion for the full year.
Adding to the optimism, the company provided full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, underscoring its confidence in sustained growth. Nomura analysts, who have a "Buy" rating on the stock, praised the Q4 2024 sales beat, attributing it to balanced growth across the US, China, and EU markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.